Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma (virgilio)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02956889
Recruitment Status : Terminated (low recruitment rate)
First Posted : November 7, 2016
Last Update Posted : January 29, 2020
Sponsor:
Information provided by (Responsible Party):
Istituto Clinico Humanitas

Tracking Information
First Submitted Date  ICMJE July 20, 2016
First Posted Date  ICMJE November 7, 2016
Last Update Posted Date January 29, 2020
Actual Study Start Date  ICMJE October 2016
Actual Primary Completion Date February 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 3, 2016)
evaluate the activity of the study therapy in terms of proportion of patients progression free [ Time Frame: 1 years ]
The primary objective is to evaluate the activity of the study therapy (radiotherapy followed by six cycles of Vismodegib 150 mg/d continuously) in terms of proportion of patients progression free at 12 months.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 3, 2016)
  • evaluate the efficacy of the study therapy in terms of progression free survival [ Time Frame: 2 years ]
    The secondary objectives are: to evaluate the efficacy of the study therapy in terms of progression free survival (PFS)
  • evaluate the efficacy of the study therapy in terms overall survival [ Time Frame: 2 years ]
    The secondary objectives are: to evaluate the efficacy of the study therapy in terms of overall survival (OS);
  • response in terms of overall response rate (ORR) [ Time Frame: 2 years ]
    to assess the response in terms of ORR (complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD))
  • duration of response [ Time Frame: 2 years ]
    to assess duration of response (DoR);
  • assess the safety in terms of incidence, type, and severity of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 2 years ]
    to assess the safety in terms of incidence, type, and severity of AEs and SAEs
  • measure the effects of skin disease on quality of life (QoL) of patients [ Time Frame: 2 years ]
    to measure the effects of skin disease on quality of life (QoL) of patients under therapy (Skindex-16)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
Official Title  ICMJE A Single Arm, Phase II, Multicenter Study To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Patients With High Risk Or Locally Advanced Basal Cell Carcinoma Not Amenable To Radical Surgery
Brief Summary

This is a Fleming-A' Hern, single arm, multicenter, no-profit, phase II study of radiotherapy and Vismodegib in adult patients with high risk or locally advanced basal cell carcinoma not amenable to radical surgery cell carcinoma (BCC) (comparator: not applicable).

The recruitment period is expected to be approximately 24 months. The trial will consist of a Screening/Baseline period (Day -28 to -1), a Treatment Period when patients will be treated with radiotherapy (4 weeks) followed by Vismodegib 150 mg/die continuously for six cycles (24 weeks).

The study will end 14 months after start of treatment of the last patient enrolled and evaluable according to primary end point.

Detailed Description

This is a Fleming-A' Hern, single arm, multicenter, no-profit, phase II study of radiotherapy and Vismodegib in adult patients with high risk or locally advanced basal cell carcinoma not amenable to radical surgery cell carcinoma (BCC) (comparator: not applicable).

The recruitment period is expected to be approximately 24 months. The trial will consist of a Screening/Baseline period (Day -28 to -1), a Treatment Period when patients will be treated with radiotherapy (4 weeks) followed by Vismodegib 150 mg/die continuously for six cycles (24 weeks).

The study will end 14 months after start of treatment of the last patient enrolled and evaluable according to primary end point.

The primary objective is to evaluate the activity of the study therapy (radiotherapy followed by six cycles of Vismodegib 150 mg/d continuously) in terms of proportion of patients progression free at 12 months.

The secondary objectives are: to evaluate the efficacy of the study therapy in terms of progression free survival (PFS) and overall survival (OS); to assess the response in terms of overall response rate (ORR) (complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)); to assess duration of response (DoR); to assess the safety in terms of incidence, type, and severity of adverse events (AEs) and serious adverse events (SAEs) ;to measure the effects of skin disease on quality of life (QoL) of patients under therapy (Skindex-16)

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Basal Cell
Intervention  ICMJE
  • Drug: Vismodegib
    Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
    Other Name: Erivedge
  • Radiation: Radiotherapy
    Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
Study Arms  ICMJE Experimental: Vismodegib & Radiotherapy

Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.

Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles

Interventions:
  • Drug: Vismodegib
  • Radiation: Radiotherapy
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 27, 2020)
14
Original Estimated Enrollment  ICMJE
 (submitted: November 3, 2016)
42
Actual Study Completion Date  ICMJE January 2020
Actual Primary Completion Date February 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Written, signed informed consent
  2. Age ≥ 18 years
  3. Histopathologic confirmation that the lesion is BCC before enrollment
  4. Patients with high risk of relapse BCC not undergone radical surgery, for which treating physician must consider the disease to be no more operable.
  5. Clinical features defining high risk of relapse include infiltrative growth margins, size, tumor location, histological subtype (the morpheaform, the sclerosing, the infiltrating, the micronodular and the metatypical subtypes are associated with higher risk of relapse as compared to the risk associated with the superficial and the nodular types), recurrent-refractory tumors (see Table 1), basal cell carcinoma size (largest tumor diameter) ≤ 5 cm for head and neck tumors
  6. Clinical features for definition of "BCC not amenable for radical surgery" include:

    • BCC that has recurred in the same location after minimum 2 surgical procedures (excluding biopsies) and/or curative resection is deemed unlikely
    • multifocal BCC or extensive tumors (see table 1) with bleeding or infected areas
    • anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation)
  7. Patients with BCCs localized where surgery is technically difficult, or would result in unacceptable tissue destruction
  8. Patients with a clinical contraindication to surgery
  9. Previous radiotherapy on other BCC
  10. Patients with measurable and/or non-measurable disease (as defined by RECIST, v1.1) are allowed
  11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  12. Adequate hematopoietic capacity, defined as the following:

    • Hemoglobin : 8.5 g/dl
    • Absolute neutrophil count (ANC) ≥ 1500/mL
    • Platelet count ≥ 75,000/mL
  13. Adequate hepatic function, defined as the following:

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN)Total bilirubin ≤ 1.5 × ULN or within 3 × ULN for patients with documented Gilbert syndrome. Adequate renal function, defined by calculated serum creatinine clearance (CrCl) ≥ 30 mL/min

  14. For women of childbearing potential, a negative serum pregnancy test within 7days prior to commencement of dosing is required.
  15. Women of child-bearing potential must use two methods of acceptable contraception including one highly effective method and a barrier method, as directed by their physician, during treatment and for at least 24 months after completion of study treatment. Highly effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (e.g., implants, injectables, combined oral contraception, or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence. Periodic abstinence (e.g., calendar, ovulation, symptothermal, and post ovulation methods) and withdrawal are not acceptable methods of contraception (See Appendix B).
  16. For male patients with female partners of childbearing potential, agreement to use a condom, even after a vasectomy, during sexual intercourse with female partners while being treated with Vismodegib, and for 2 months after completion of study treatment
  17. Agreement not to donate blood or blood products during the study and for at least 24 months after completion of study treatment (Vismodegib).

Exclusion Criteria:

  1. Inability or unwillingness to swallow capsules
  2. Inability or unwillingness to comply with study procedures
  3. Pregnancy or lactation (lactation not allowed for at least 24 months after completion of study treatment)
  4. Concurrent non-protocol-specified anti-tumor therapy (e.g., chemotherapy, other targeted therapy, photodynamic therapy, including participation in an experimental drug study)
  5. Metastatic BCC
  6. Gorlin Syndrome or any other contraindication to radiotherapy
  7. Recent (i.e., within the past 28 days prior to enrollment in this study) or current participation in another experimental drug study
  8. Uncontrolled medical illness, including advanced malignancies, at the discretion of the Investigator
  9. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Italy
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02956889
Other Study ID Numbers  ICMJE ONC-2015-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: not planned
Responsible Party Istituto Clinico Humanitas
Study Sponsor  ICMJE Istituto Clinico Humanitas
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Armando Santoro, MD Istituto Clinico Humanitas
PRS Account Istituto Clinico Humanitas
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP